Autolus Therapeutics plc
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · London, United Kingdom
AUTL chart
What traders are saying about $AUTL
Latest postsAutolus Therapeutics plc news
- Autolus Therapeutics to present at Jefferies Gl...
Pluang ·
- Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Yahoo Finance ·
- Autolus Therapeutics plc Stock Price Prediction: Today, Tomorrow, Next Week (AUTL)
Traders Union ·
- Autolus Therapeutics Stock Price Forecast. Should You Buy AUTL?
StockInvest.us ·
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
Yahoo Finance ·
- The first four patients in a cell-therapy trial all had rapid, complete blood responses
Stock Titan ·
- Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
Yahoo Finance ·
- All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Yahoo Finance ·
- Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Yahoo Finance ·
- AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black
Yahoo Finance ·
- Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Yahoo Finance ·
Autolus Therapeutics plc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $75.4M | $10.1M | – | – |
| Net income | -$287.5M | -$220.7M | -$208.4M | -$148.8M |
| Diluted EPS | $-1.08 | $-0.86 | $-1.20 | $-1.57 |
| Total assets (year end) | $589.1M | $782.7M | $375.4M | $490.3M |
| Cash and equivalents (year end) | $104.1M | $227.4M | $239.6M | $382.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Autolus Therapeutics plc
- Ticker
- AUTL (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- London, United Kingdom
- Incorporated in
- United Kingdom
- Fiscal year end
- December 31
- SEC CIK
- 1730463
- Former names
- Autolus Therapeutics Ltd
Frequently asked questions
What exchange is Autolus Therapeutics plc listed on?
Autolus Therapeutics plc trades on the Nasdaq under the ticker symbol AUTL.
What industry is Autolus Therapeutics plc in?
Autolus Therapeutics plc is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Autolus Therapeutics plc headquartered?
Autolus Therapeutics plc's business address on file with the SEC is in London, United Kingdom.
When does Autolus Therapeutics plc's fiscal year end?
Autolus Therapeutics plc's fiscal year ends on December 31.
How much revenue did Autolus Therapeutics plc report?
Autolus Therapeutics plc reported $75.4M in revenue for calendar year 2025, according to its SEC filings.